Q-omics provides the consensus-scored R3HDM2 profile across patient tissues and cancer cell-line models. R3HDM2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, R3HDM2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, R3HDM2 RNA expression shows 20,524 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where R3HDM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for R3HDM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes R3HDM2 survival associations across molecular data types. R3HDM2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible R3HDM2 RNA expression–survival associations across cancer types. High R3HDM2 expression shows unfavorable associations in KICH, CESC, COAD and BLCA, but favorable associations in UCS and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for R3HDM2 RNA expression.
This table summarizes R3HDM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for R3HDM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. R3HDM2 shows higher tumor expression in KIRC, HNSC, STAD, COAD, LIHC and BLCA. The KIRC box plot shows higher R3HDM2 RNA expression in tumor versus normal tissue (log2 FC = +0.452, t-test p < 0.001).
This table shows molecular features associated with R3HDM2 in patient tissues and cancer cell lines. In patient samples, R3HDM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, R3HDM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
